Telavancin, a new lipoglycopeptide antimicrobial, in complicated skin and soft tissue infections

Infection and Drug Resistance

Volumn 4, Issue 1, 2011, Pages 87-95

  Saraf, Lida Jafari ^a   Wilson, Samuel Eric ^b  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Complicated skin and skin structure infections; Gram positive bacteria; Methicillin resistant staphylococcus aureus; MRSA; Telavancin

Indexed keywords

BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFTAROLINE; CEFTOBIPROLE; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; CLOXACILLIN; COTRIMOXAZOLE; DAPTOMYCIN; LINEZOLID; MINOCYCLINE; NAFCILLIN; OXACILLIN; TELAVANCIN; VANCOMYCIN;

ABDOMINAL PAIN; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANXIETY; APPLICATION SITE PAIN; ARTICLE; ATELECTASIS; BACTEREMIA; BACTERIAL SKIN DISEASE; BACTERIUM ISOLATION; CHILL; CONSTIPATION; CREATININE BLOOD LEVEL; DECREASED APPETITE; DIARRHEA; DISSEMINATED INTRAVASCULAR CLOTTING; DIZZINESS; DOSE KIDNEY FUNCTION RELATION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENCY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EOSINOPHILIA; ERYTHEMA; FATIGUE; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEARING LOSS; HEART ATRIUM FIBRILLATION; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOTENSION; IN VITRO STUDY; INFECTION COMPLICATION; INSOMNIA; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LIVER FAILURE; LOBAR PNEUMONIA; LUNG INFILTRATE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MICROALBUMINURIA; MULTIPLE ORGAN FAILURE; MYOSITIS; NAUSEA; NONHUMAN; PRURITUS; QT PROLONGATION; RASH; RECOMMENDED DRUG DOSE; RESPIRATORY FAILURE; SEPSIS; SIDE EFFECT; SINGLE DRUG DOSE; SKIN ABSCESS; SKIN INFECTION; SOFT TISSUE INFECTION; SUICIDAL IDEATION; TASTE DISORDER; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT INDICATION; VOMITING; WOUND HEMORRHAGE; WOUND INFECTION;

EID: 79952660496     PISSN: 11786973     EISSN: None     Source Type: Journal    
DOI: 10.2147/IDR.S5327     Document Type: Article

References (48)

1. Deleo FR, Chambers HF. Reemergence of antibiotic-resistant Staphylococcus aureus in the genomics era. J Clin Invest. 2009;119(9): 2464-2474.
2. Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA. 2007; 298(15):1763-1771.
3. Barlett JJ. Methicillin resistant Staphylococcus aureus infections. International AIDS Society USA topics in HIV Medicine. 11th Annual clinical update for the Ryan White HIV/AIDS Program clinicians. Top HIV Med. 2008;16(5):151-155.
4. Rubin RJ, Harrington LA, Poon A, et al. The economic impact of Staphylococcus aureus infection in New York City hospitals. Emerg Infect Dis. 1999;5(1):9-17.
5. Jevans MP, Coe AW, Parker MI. Methicillin resistance in staphylococci. Lancet. 1963;1(7287):904-907.
6. Cosgrove SE, Sakoulas G, Pevencevich EN, Schwaber MJ, Karchmer AW, Carmell Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: A meta analysis. Clin Infect Dis. 2003;36(1):53-59.
7. Kowalski TJ, Berbari EF, Osmon DR. Epidemiology, treatment and prevention of the community acquired methicillin resistant Staphylococcus aureus infections. Mayo Clin Proc. 2005;80(9): 1201-1208.
8. National Nosocomial Infection Surveillance system. National Nosocomial Infection: Surveillance system report data summary from January 1992 to June 2000. Am J Infect Control. 2000;28(6):429-448.
9. Boyle-Vavra S, Daum RS. Community-acquired methicillin-resistant Staphylococcus aureus: The role of Panton-Valentine leukocidin. Lab Invest. 2007;87(1):3-9.
10. Lina G, Piémont Y, Godail-Gamot F, et al. Involvement of Panton- Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis. 1999;29(5):1128-1132.
11. Farley JE. Epidemiology, clinical manifestations, and treatment options for skin and soft tissue infection caused by community acquired methicillin-resistant Staphylococcus aureus. J Am Acad Nurse Pract. 2008;20(2):85-92.
12. Miller LG, Perdreau-Remington F, Rieg G, et al. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med. 2005;352(14): 1445-1453.
13. Lowy FD. Staphylococcus aureus infections. N Engl J Med. 1998; 339(8):520-532.
14. Otto M. Understanding the epidemic of community associated MRSA and finding a cure: Are we asking the right questions? Expert Rev Anti Infect Ther. 2009;7(2):141-143.
15. Klevens RM, Morrison MA, Fridkin SK, et al. Community-associated methicillin-resistant Staphylococcus aureus and healthcare risk factors. Emerg Infect Dis. 2006;12(12):1991-1993.
16. Leonard SN, Rybak MJ. Telavancin: An antimicrobial with a multifunctional mechanism of action for the treatment of serious gram positive infections. Pharmacotherapy. 2008;28(4):458-468.
17. Corey GR, Stryjewski ME, Weyenberg W, Yasothan U, Kirkpatrick P. Televancin. Nat Rev Drug Discov. 2009;8(12):929-930.
18. Judice JK, Pace JL. Semi-synthetic glycopeptide antibacterials. Bioorg Med Chem Lett. 2003;13(23):4165-4168.
19. Laohavaleeson S, Nicolau DP. Cost effectiveness of telavancin versus vancomycin for treatment of complicated skin and skin structure infections. Pharmacotherapy. 2008;28(12):1471-1482.
20. Laohavaleeson S, Kuti JL, Nicolau DP. Telavancin a novel lipoglycopeptide for serious gram positive infections. Expert Opin Investig Drugs. 2007;16(3):347-357.
21. Higgins DL, Chang R, Debabov DV, et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2005;49(3):1127-1134.
22. Mendes RE, Moet GJ, Janechek MJ, Jones RN. In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates. Antimicrob Agents Chemother. 2010;54(6): 2704-2706.
23. Pace JL, Judice JK. Telavancin (Theravance). Curr Opin Investig Drugs. 2005;6(2):216-225.
24. Wilson SE, O'Riordan W, Hopkins A, Friedland HD, Barriere SL, Kitt MM; ATLAS Investigators. Telavancin versus vancomycin for the treatment of complicated skin and skin structure infections associated with surgical procedures. Am J Surg. 2009;197(6):791-796.
25. Gusky MT, Tsuji BT. A comparative review of the lipoglycopeptides: Oritavancin, delbavancin and telavancin. Pharmacotherapy. 2010; 30(1):80-94.
26. Stryjewski ME, O'Riordan WD, Lau WK, et al. Telavancin versus standard therapy for treatment of complicated skin and soft tissue infections due to gram-positive bacteria. Clin Infect Dis. 2005;40(11): 1601-1607.
27. Stryjewski ME, Chu VH, O'Riordan WD, et al. Telavancin versus standard therapy for the treatment of complicated skin and skin structure infections caused by Gram positive bacteria: FAST 2 Study. Antimicrob Agents Chemother. 2006;3:826-867.
28. Scheinfeld N. A comparison of available and investigational antibiotics for complicated skin and skin infections and treatment resistant Staphylococcus aureus and enterococcus. J Drugs Dermatol. 2007;6(1): 97-103.
29. Shaw JP, Seroogy J, Kaniga K, Higgins DL, Kitt M, Barriere S. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob Agents Chemother. 2005; 49(1):195-201.
30. Wong SL, Barriere SL, Kitt MM, Goldberg MR. Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects. J Antimicrob Chemother. 2008;62(4):780-783.
31. Duchin K, Shaw J, Spencer E, Seroogy J, Barriere S, Wilbraham D. Single dose pharmacokinetics (PK) of telavancin in healthy elderly subjects. Poster P1028 presented at the 14th European Congress of Clinical Microbiology and Infectious Disease. Prague, Czech Republic, May 1-4, 2004.
32. Patel JH, Churchwell MD, Seroogy JD, Barriere SL, Grio M, Mueller B. Telavancin and hydroxy propyl-beta-cyclodextrin clearance during continuous renal replacement therapy: An in vitro study. Int J Artif Organs. 2009;32(10):745-751.
33. Goldberg MR, Wong SL, Shaw JP, Kitt MM, Barriere SL. Lack of effect of moderate hepatic impairment on the pharmacokinetics of telavancin. Pharmacotherapy. 2010;30(1):35-42.
34. Goldberg MR, Wong SL, Shaw JP, Kitt MM, Barriere SL. Single-dose pharmacokinetics and tolerability of telavancin in elderly men and women. Pharmacotherapy. 2010;30(8):806-811.
35. Sun HK, Duchin K, Nightingale CH, Shaw JP, Seroogy J, Nicolau DP. Tissue penetration of telavancin after intravenous administration in healthy subjects. Antimicrob Agents Chemother. 2006;50(2):788-790.
36. Lodise TP Jr, Gotfried M, Barriere S, Drusano GL. Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob Agents Chemother. 2008;52(7):2300-2304.
37. Gotfried MH, Shaw JP, Benton BM, et al. Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics. Antimicrob Agents Chemother. 2008;52(1):92-97.
38. Dunbar LM, Tang DM, Manausa RM. A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI). Ther Clin Risk Manage. 2008;4(1):235-244.
39. Dancer SJ. The effect of antibiotics on methicillin resistant Staphylococcus aureus. J Antimicrob Chemother. 2008;61(2):246-253.
40. Wong G, Hindler JF, Ward KW, Bruckner DA. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5 year period. J Clin Microbiol. 2006;44(11): 3883-3886.
41. Tenover FC, Moellering RC Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis. 2007;44(9):1208-1215.
42. Llera JL, Levy RC. Treatment of cutaneous abscess: A double-blind clinical study. Ann Emerg Med. 1985;14(1):15-19.
43. Khatib R, Johnson LB, Sharma M, Fakih MG, Ganga R, Riederer K. Persistent Staphylococcus aureus bacteremia: Incidence and outcome trends over time. Scand J Infect Dis. 2009;41(1):4-9.
44. Chambers HF, DeLeo FR. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microb. 2009;7(9):629-641.
45. Parish D, Scheinfeld N. Ceftaroline fosamil, a cephalosporin derivative for the potential treatment of MRSA infection. Curr Opin Investig Drugs. 2008;9(2):201-209.
46. Anderson SD, Gums JG. Ceftobiprole: An extended-spectrum anti- methicillin-resistant Staphylococcus aureus cephalosporin. Ann Pharmacother. 2008;42(6):806-816.
47. Shaw KJ, Poppe S, Schaadt R, et al. In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains. Antimicrob Agents Chemother. 2008;52(12):4442-4447.
48. Strijewski ME, Graham DR, Wilson SE, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin structure infections caused by gram positive organism. Clin Infect Dis. 2008;46(11): 1683-1693.